P-LLY Cautionary Statement Regarding Forward-Looking Statements This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about retatrutide as a potential treatment for adults with obesity or overweight and at least one weight-related comorbidity, potential efficacy and tolerability of retatrutide, and the timeline for future readouts, presentations, and other milestones relating to retatrutide and its clinical trials and reflects Lilly's current beliefs and expectations
Attach a new needle if required by the pen
Avoid high-fat and greasy foods during the first two weeks after each dose increase, as fat takes longest to digest and compounds the slowed gastric emptying effect
Alright, thats enough political stuff you guys probably get enough of that elsewhere
Every effort has been made to ensure the accuracy of pricing, product availability, brand representation, and clinical descriptions at the time of publication
Concerned about weight gain, diabetes risk, or metabolic health
